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Introduction
The 5-fluoro-2-oxindole (5F2O) moiety is a common structural
component of many new drugs in a variety of pharmaceutical
classes, including anti-cancer and anti-inflammatory drugs. The
reactivity of this moiety with oxidative enzymes in the human liver,
namely CYP enzymes, is an important consideration when
assessing the potential for toxic products of degradation or adverse
side effects. These oxidative reactions are dependent on NADPH in
the liver, and they are catalyzed by human S9 liver enzymes.
Determining the structure of the major products of reactions
catalyzed in the liver is necessary when evaluating the possible
toxicity associated with drug candidates, such as Ciprofloxacin and
Tylenol, that contain the 5F2O moiety.
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1. Which conditions are required to view 5F2O on an HPLC?
2. Which reaction conditions produce peak degradation when
viewed on the HPLC?
B
3. Which conditions are required to view 5F2O on LCMS?

4. What is the structure of the metabolites produced by the reaction
of CYP2A6R and 5F2O catalyzed by NADPH?

Ciprofloxacin

Anti-Cancer
Drugs
(Figure 1.)

Figure 3. A bottle of ciprofloxacin. From PetMeds:
"Ciprofloxacin,"
n.d., https://www.1800petmeds.com/Ciprofloxacinprod11076.html Creative Commons BY-SA 4.0
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In order to determine the structures of these products, high
performance liquid chromatograph (HPLC) and liquid
chromatography-mass spectrometry (LCMS) conditions must first
be established such that a consistent peak can be viewed at a
consistent retention time each run. After these conditions are
established, reaction parameters must also be generated in such a
way that degradation of the 5F2O peak can be viewed on the
aforementioned instruments, and a new peak, the product peak, can
be visualized. Using LCMS, the molecular weight of the product
can be determined and used to identify the product formed by
CYP2A6R degradation of 5F2O.
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Figure 1. Chemical structures for oxindolederived compounds. Current therapies for antiinflammatory, antibiotics, and anti-cancer, such
as Acetaminophen, Ciprofloxacin, and
Famitinib, contain oxindole moieties.

General HPLC Protocols
1. 5F2O diluted in methanol to 200mM stock.
2. Diluted to 1-20mM in reaction.
3. Transferred 500uL of reaction to HPLC vial.
4. Inject 25uL on C18 reverse phase column with a flow
rate of 1mL/min for 10 minutes.
5. Viewed at 214nm.
6. Different ratios based on individual method trials, but
consistent solvents of diH2O (0.1% TFA) and
acetonitrile (0.1% TFA).
7. Increased proportion of diH2O:ACN to shift peak
further right (will come off column later).
Individual Methods Used
1. Oxindole.M was a gradient method
100% diH2O to 0% and 0% ACN to
minutes.
2. OxindoleTrial1.M was an isocratic
method with 80:20 diH2O:ACN.
3. OxindoleTrial2.M was an isocratic
65:35 diH2O:ACN.
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Reaction With Human Liver Enzymes
1. A reaction with final volume of 1mL contained the
following reagents: 1mM 5F2O, 1mM NADPH,
50mM phosphate buffer, pH 7.5, 1uL CYP2A6R,
diH2O.
2. Incubated at 35 °C for 10 minutes.
3. Quenched with 1mM methanol.
4. Negative control generated by omitting NADPH
5. 500uL of each reaction transferred to HPLC vial.

Conclusion
Figure 4. A bottle of Tylenol. Photo by Alexa Deckert.

5-fluoro-2-oxindole can be detected by HPLC at 214nm
using a non-gradient method. This detection is
optimized at a 65:35 diH2O:ACN isocratic method to
consistently separate the peak from the solvent peaks.
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Future Work

Figure 2. Consistency with OxindoleTrial2.M. 20mM
5F2O was run using HPLC OxindoleTrial2.M which
consisted of 65:35 diH2O:ACN. This method produced
consistent peaks amongst various trials over a period of
weeks. This method was implicated in further
experimentation with human liver enzymes.

Figure 5. Metabolites of the reaction between CYP
enzymes and 5F2O. Several products were
hypothesized based on LC/MS and HPLC data from
other previous research.

Future work will begin with running additional reactions
with human liver enzymes to find which conditions will
optimize a product peak. Further work will feature the
development of a protocol for LCMS analysis of both
product and substrate peaks. The products of the
reaction will then be analyzed to determine their
structure and relative toxicity.

